These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19208456)

  • 1. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.
    Longo O; Tripiciano A; Fiorelli V; Bellino S; Scoglio A; Collacchi B; Alvarez MJ; Francavilla V; Arancio A; Paniccia G; Lazzarin A; Tambussi G; Din CT; Visintini R; Narciso P; Antinori A; D'Offizi G; Giulianelli M; Carta M; Di Carlo A; Palamara G; Giuliani M; Laguardia ME; Monini P; Magnani M; Ensoli F; Ensoli B
    Vaccine; 2009 May; 27(25-26):3306-12. PubMed ID: 19208456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The preventive phase I trial with the HIV-1 Tat-based vaccine.
    Ensoli B; Fiorelli V; Ensoli F; Lazzarin A; Visintini R; Narciso P; Di Carlo A; Tripiciano A; Longo O; Bellino S; Francavilla V; Paniccia G; Arancio A; Scoglio A; Collacchi B; Ruiz Alvarez MJ; Tambussi G; Tassan Din C; Palamara G; Latini A; Antinori A; D'Offizi G; Giuliani M; Giulianelli M; Carta M; Monini P; Magnani M; Garaci E
    Vaccine; 2009 Dec; 28(2):371-8. PubMed ID: 19879233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.
    Ensoli B; Fiorelli V; Ensoli F; Lazzarin A; Visintini R; Narciso P; Di Carlo A; Monini P; Magnani M; Garaci E
    AIDS; 2008 Oct; 22(16):2207-9. PubMed ID: 18832884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
    Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial.
    Boffito M; Fox J; Bowman C; Fisher M; Orkin C; Wilkins E; Jackson A; Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
    Vaccine; 2013 Nov; 31(48):5680-6. PubMed ID: 24120550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory clinical studies of a synthetic HIV-1 Tat epitope vaccine in asymptomatic treatment-naïve and antiretroviral-controlled HIV-1 infected subjects plus healthy uninfected subjects.
    Goldstein G; Chicca JJ
    Hum Vaccin Immunother; 2012 Apr; 8(4):479-85. PubMed ID: 22336878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau.
    Román VR; Jensen KJ; Jensen SS; Leo-Hansen C; Jespersen S; da Silva Té D; Rodrigues CM; Janitzek CM; Vinner L; Katzenstein TL; Andersen P; Kromann I; Andreasen LV; Karlsson I; Fomsgaard A
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1504-12. PubMed ID: 23634822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
    Gorse GJ; Baden LR; Wecker M; Newman MJ; Ferrari G; Weinhold KJ; Livingston BD; Villafana TL; Li H; Noonan E; Russell ND;
    Vaccine; 2008 Jan; 26(2):215-23. PubMed ID: 18055072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
    J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
    Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
    AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.
    Kelleher AD; Puls RL; Bebbington M; Boyle D; Ffrench R; Kent SJ; Kippax S; Purcell DF; Thomson S; Wand H; Cooper DA; Emery S
    AIDS; 2006 Jan; 20(2):294-7. PubMed ID: 16511428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.
    Bellino S; Francavilla V; Longo O; Tripiciano A; Paniccia G; Arancio A; Fiorelli V; Scoglio A; Collacchi B; Campagna M; Lazzarin A; Tambussi G; Din CT; Visintini R; Narciso P; Antinori A; D'Offizi G; Giulianelli M; Carta M; Di Carlo A; Palamara G; Giuliani M; Laguardia ME; Monini P; Magnani M; Ensoli F; Ensoli B
    Rev Recent Clin Trials; 2009 Sep; 4(3):195-204. PubMed ID: 20028332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects.
    Wallace MR; Brandt CJ; Earhart KC; Kuter BJ; Grosso AD; Lakkis H; Tasker SA
    Clin Infect Dis; 2004 Oct; 39(8):1207-13. PubMed ID: 15486846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial.
    Kemper CA; Haubrich R; Frank I; Dubin G; Buscarino C; McCutchan JA; Deresinski SC;
    J Infect Dis; 2003 Apr; 187(8):1327-31. PubMed ID: 12696015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
    Birx DL; Loomis-Price LD; Aronson N; Brundage J; Davis C; Deyton L; Garner R; Gordin F; Henry D; Holloway W; Kerkering T; Luskin-Hawk R; McNeil J; Michael N; Foster Pierce P; Poretz D; Ratto-Kim S; Renzullo P; Ruiz N; Sitz K; Smith G; Tacket C; Thompson M; Tramont E; Yangco B; Yarrish R; Redfield RR
    J Infect Dis; 2000 Mar; 181(3):881-9. PubMed ID: 10720508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization.
    Gringeri A; Santagostino E; Mannucci PM; Tradati F; Cultraro D; Buzzi A; Criscuolo M; David A; Guillemot L; Barré-Sinoussi F
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):978-88. PubMed ID: 7914235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.
    Ensoli F; Cafaro A; Casabianca A; Tripiciano A; Bellino S; Longo O; Francavilla V; Picconi O; Sgadari C; Moretti S; Cossut MR; Arancio A; Orlandi C; Sernicola L; Maggiorella MT; Paniccia G; Mussini C; Lazzarin A; Sighinolfi L; Palamara G; Gori A; Angarano G; Di Pietro M; Galli M; Mercurio VS; Castelli F; Di Perri G; Monini P; Magnani M; Garaci E; Ensoli B
    Retrovirology; 2015 Apr; 12():33. PubMed ID: 25924841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration.
    Caputo A; Castaldello A; Brocca-Cofano E; Voltan R; Bortolazzi F; Altavilla G; Sparnacci K; Laus M; Tondelli L; Gavioli R; Ensoli B
    Vaccine; 2009 Jun; 27(27):3605-15. PubMed ID: 19464541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
    Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
    Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of antiretroviral immunotherapy trials with potentially non-normal and incomplete longitudinal data.
    Mogg R; Mehrotra DV
    Stat Med; 2007 Feb; 26(3):484-97. PubMed ID: 16625520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.